heterophile
antipolyvalent
soravtansine
-zumab
countercorrelated
bispecific
zanolimumab
Ab
idiospecific
antiantibody
polyantibody
mapatumumab
intrabody
biciromab
zolimomab
alacizumab
oportuzumab monatox
sulesomab
conatumumab
durvalumab
heteroclitic
evolocumab
antiidiotypic
-axo-
polyvalent
fontolizumab
ocrelizumab
patritumab
ipilimumab
-ab
lucatumumab
carlumab
brentuximab
agonistic monoclonal antibody
immunospecific
antigenomic
tigatuzumab
immunoprecipitant
panitumumab
antinucleosome
naptumomab estafenatox
oleclumab
drozitumab
dacetuzumab
nofetumomab
-a-
cedelizumab
presentation
immunoprobe
tenatumomab